H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

Slides:

Advertisements

Similar presentations

Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD

Advertisements

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.

Age as a prognostic factor for head and neck squamous cell carcinoma: should older patients be treated differently? Udi Cinamon 1, Michael P. Hier 2, Martin.

National Institute of Oncology Rabat-Morocco. National Institute of Oncology I.N.O. Rabat, Morocco : New Cases.

EDWARD WEISBERGER MD OTOLARYNGOLOGY/HEAD AND NECK SURGERY INDIANA UNIVERSITY MEDICAL CENTER.

Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.

Indications for adjuvant radiation therapy with or without lymph nodes in salivary gland cancer Claus Rödel Department of Radiation Therapy University.

First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Mauricio A. Moreno, M.D. Assistant Professor Department of Otolaryngology- Head and Neck Surgery University or Arkansas for Medical Sciences Mauricio A.

Radiotherapy for Kidney cancer

PET after Chemotherapy in Rhabdomyosarcoma Connective Tissue Oncology Society November 19, 2005 Michelle L. Klem, Leonard H. Wexler, Ravinder Grewal, Heiko.

Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.

Evaluating a Nomogram for the Development of Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Treated with 3D and Intensity Modulated.

Birga Terlunen-Traboldt ENT-Journal Club Need for Neck dissection after Radiochemotherapy? A study of the French GETTEC Group Vedrine P;Thariat J;Hitier.

Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for.

DAHANCA 16 Planned post-radiation neck dissection vs salvage neck dissection in patients with N2-3 SCC of the head and neck treated with primary radiotherapy.

Resection For Lung Metastases M62 Coloproctology Course.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

LUNG CANCER Dr.Mohammadzadeh. Lung cancer is the leading cancer killer in the United States. Every year, it accounts for 30% of all cancer deaths— more.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

WHAT ARE THE RISK FACTORS FOR LUNG CANCER? SMOKING.

AJCC Staging Moments AJCC TNM Staging 7th Edition Supraglottic Larynx Case #2 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New.

ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/2/09.

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Definitive radiotherapy for head and neck cancer: the use of physical exam versus computed tomography to manage the post-RT neck Stanley Liauw*, Robert.

(4) Radiation Therapy Oncology Group (RTOG)

Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10.

Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels XiaoShen Wang*, ChaoSu.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

The Neck Jochen A. Werner Marburg, Germany. The Neck in squamous cell carcinoma (HNSCC) in cancer of unknown primary in skin cancer in salivary gland.

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

HIGH DOSE RADIOTHERAPY IN THE TREATMENT OF PLEURAL MESOTHELIOMA AFTER PLEURECTOMY/DECORTICATION OR BIOPSY: LONG TERM FOLLW UP, ACUTE AND LATE TOXICITY.

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Background Carcinoma of the anal canal accounts for 1.5% of all digestive system malignancies in the United States. 1 The annual incidence continues to.

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

1 Poster # 1100: Temporal Regression of Cervical Lymph Node in N2-N3 Head and Neck Cancer Treated with Primary Radiotherapy  Chemotherapy: stratified.

Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma JIN Chen, YAO Lie, LONG.

Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Oral Cavity Version Table of Content StagingStaging, Manuscript Taipei Veterans.

M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.

Head & Neck Ca. (Epithelial tumors) Mohamad KADRI. MD. Clinical oncology. Medical director of AlBerouni University Hospital President of Syrian Association.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Authors: Syed H. Jafri ¹, Angel I. Blanco¹, Bonnie A. Labdi², Shan Guo¹. UT Houston department of medicine, Division of Oncology Department of Pharmacy.

Dynamic Contrast Enhanced (DCE)-MRI as a Predictor of Response in Head & Neck Squamous Cell Carcinoma (HNSCC) : Initial Analysis A.Shukla-Dave 1,2, N.

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Arterial spin labeling MR imaging of head and neck squamous cell carcinoma Abdel Razek A Department of Radiology Mansoura Faculty of medicine. Mansoura.

Taipei Veterans General Hospital Practices Guidelines Oncology Oral Cavity Cancer Version

NICE GUIDELINES February 2016

Brain imaging prior to lung cancer resection

Summary of staging criteria for cancers of the oral cavity, oropharynx, hypopharynx, and larynx. Carcinoma in situ is stage 0, and presence of distant.

CORRELATION BETWEEN AREAS OF HIGH FDG UPTAKE ON PRE-TREATMENT PET/CT AND PREFERENTIAL SITES OF LOCAL RELAPSE AFTER CHEMO-RADIOTHERAPY FOR HEAD AND NECK.

Short-term outcome of neo-adjuvant chemotherapy

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Cancer Waiting Times, UK countries England Wales Scotland

Clinicopathological features and outcome of Head & Neck Cancer in Pakistan 1A Jamshed, 1R Hussain, 2S Jamshed, 1A A Syed, 1A Loya, 1M A Shah, 1U Majeed.

Analysis of the Incidence and Factors Predictive of Outcome in Head and Neck Cancer Patients with Pulmonary Nodules Richard Green MBBS, DOHNS1 Mark Macmillan2.

Basile Pache, Antonia Digklia*, Nicolas Demartines, Maurice Matter.

Brain imaging prior to lung cancer resection

Prof. Shaila Anwar Professor Obs & Gynae

Prof.S.M.Haider Faisal Hameed Wahab Kadri

Dr T P E Wells 13 July 2018 Breast SSG Bath

Best Practices in Lymph Node Mapping and Localization: Melanoma

Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program

Presentation transcript:

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology

No Disclosures

Purpose To evaluate whether involvement of various Nodal Levels are associated with a different risk of Distant Metastasis (DM) in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).

Methods - A prospective study have accrued 92 HNSCC patients (Stage II-IVa). - Treated using Intensity Modulated Radiation Therapy on a Helical Tomotherapy unit. - Total dose of 70 Gy +/- Concurrent Platinum Based Chemotherapy patients included in this report have completed the treatment as per the protocol. - The majority of patients were males (69 patients) with a median age of 60 years (39-87). - Primary involved sites were Oropharynx (59 patients), Larynx (10), Nasopharynx (7), Hypopharynx (6), Oral Cavity (3) and Unknown Primary (3). - Lymph Nodal (LN) levels were identified using their diagnostic/planning CT scans, MRI or FDG-PET scans based on size/morphology/contrast enhancement or FDG avidity. - Different LN levels were defined based on the Consensus Guidelines (V.Gregoire, et al). - For each LN level, the percentage crude risk of DM was identified by calculating “No. o f patients with the involved LN Level who developed DM” / “the total number of patients who had that LN level involved”.

Results - The patients were followed-up for a median period of 31 months (3-65). - Thirteen patients (15%) developed Distant Metastasis with a median time to DM of 20 months (1-44 months). - Level I (9 pts), Level II (61 pts), Level III (40 pts), Level IV (18 pts), Level V (13 pts) and RP (6 pts). - Out of the 13 patients who developed DM, the LN levels involved were: Level I (3 pts), Level II (12 pts), Level III (8 pts), Level IV (7 pts), Level V (6 pts) and RP group (2 pts). - The crude risk of DM stratified based on each LN level was calculated as follows: Level I (33%), Level II (20%), Level III (20%), Level IV (39%), Level V (46%) and RP group (33%). - The 3 patients with DM who had Level I LN involved had extra-oral cavity primaries with multi-level involvement (Supraglottic Larynx “level I-V”, Base of Tongue ”Levels I,III,IV” and Tonsil “Level I-II”). - The most common site for DM was lung (8 pts), followed by bones (5 pts), liver (2 pts) and brain (1 pt).

Conclusions Patients with HNSCC who have involved Lymph Node levels IV, V or RP group are associated with % risk of DM in this cohort and should be considered to be further assessed for the role of adjuvant systemic therapy.